Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has announced new employee inducement grants under its 2022 Inducement Equity Plan. The company has awarded equity grants to seven new employees, including:
- 65,027 shares as inducement stock options with an exercise price of $35.15
- 48,773 shares as inducement restricted stock units
The stock options will vest 25% after one year from each employee's start date, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These grants, totaling 113,800 shares, are designed to attract new talent and comply with Nasdaq Listing Rule 5635(c)(4).
Scholar Rock (NASDAQ: SRRK), un'azienda biofarmaceutica in fase avanzata, ha annunciato nuove concessioni di indennità per i dipendenti nell'ambito del suo Piano di Indennità Azionaria 2022. L'azienda ha assegnato concessioni azionarie a sette nuovi dipendenti, tra cui:
- 65.027 azioni come opzioni su azioni di indennità con un prezzo di esercizio di $35,15
- 48.773 azioni come unità azionarie vincolate di indennità
Le opzioni azionarie matureranno il 25% dopo un anno dalla data di inizio di ciascun dipendente, con il restante 75% che maturerà in 12 rate trimestrali. Le unità azionarie vincolate matureranno in quattro rate annuali uguali. Queste concessioni, per un totale di 113.800 azioni, sono progettate per attrarre nuovi talenti e per conformarsi alla Regola di Quotazione Nasdaq 5635(c)(4).
Scholar Rock (NASDAQ: SRRK), una empresa biofarmacéutica en etapa avanzada, ha anunciado nuevas concesiones de incentivos para empleados bajo su Plan de Equidad de Incentivos 2022. La empresa ha otorgado concesiones de acciones a siete nuevos empleados, incluyendo:
- 65,027 acciones como opciones sobre acciones de incentivo con un precio de ejercicio de $35.15
- 48,773 acciones como unidades de acciones restringidas de incentivo
Las opciones sobre acciones se consolidarán en un 25% después de un año desde la fecha de inicio de cada empleado, y el 75% restante se consolidará en 12 cuotas trimestrales. Las unidades de acciones restringidas se consolidarán en cuatro cuotas anuales iguales. Estas concesiones, que totalizan 113,800 acciones, están diseñadas para atraer nuevo talento y cumplir con la Regla de Cotización Nasdaq 5635(c)(4).
스콜라 록 (NASDAQ: SRRK), 후기 단계의 바이오 제약 회사가 2022년 유인 주식 계획에 따라 새로운 직원 유인 보상을 발표했습니다. 회사는 7명의 새로운 직원에게 주식 보상을 수여했습니다. 포함 내용은:
- 65,027주 유인 스톡 옵션, 행사 가격은 $35.15
- 48,773주 유인 제한 주식 단위
스톡 옵션은 각 직원의 시작일로부터 1년 후 25%가 베스팅되며, 나머지 75%는 12회의 분기별 할부로 베스팅됩니다. 제한 주식 단위는 4회의 동등한 연간 할부로 베스팅됩니다. 총 113,800주에 달하는 이 보상은 새로운 인재를 유치하고 Nasdaq 상장 규칙 5635(c)(4)에 부합하기 위해 설계되었습니다.
Scholar Rock (NASDAQ: SRRK), une entreprise biopharmaceutique en phase avancée, a annoncé de nouvelles subventions d'incitation pour les employés dans le cadre de son Plan d'Équité d'Incitation 2022. L'entreprise a attribué des subventions d'actions à sept nouveaux employés, y compris :
- 65 027 actions sous forme d'options d'achat d'actions d'incitation avec un prix d'exercice de 35,15 $
- 48 773 actions sous forme d'unités d'actions restreintes d'incitation
Les options d'achat d'actions acquerront 25 % après un an à compter de la date de début de chaque employé, le reste de 75 % étant acquis en 12 versements trimestriels. Les unités d'actions restreintes seront acquises en quatre versements annuels égaux. Ces subventions, totalisant 113 800 actions, sont conçues pour attirer de nouveaux talents et se conformer à la règle de cotation Nasdaq 5635(c)(4).
Scholar Rock (NASDAQ: SRRK), ein Biopharmaunternehmen in der späten Entwicklungsphase, hat neue Mitarbeiteranreize im Rahmen seines Equity-Plan 2022 bekannt gegeben. Das Unternehmen hat sieben neuen Mitarbeitern Aktienoptionen gewährt, darunter:
- 65.027 Aktien als Anreiz-Aktienoptionen mit einem Ausübungspreis von 35,15 $
- 48.773 Aktien als Anreiz-Restricted Stock Units
Die Aktienoptionen werden zu 25 % nach einem Jahr ab dem Einstellungsdatum jedes Mitarbeiters fällig, während die verbleibenden 75 % in 12 vierteljährlichen Raten fällig werden. Die Restricted Stock Units werden in vier gleichen jährlichen Raten fällig. Diese Zuwendungen, die insgesamt 113.800 Aktien ausmachen, sollen neue Talente anziehen und den Nasdaq-Listing-Regeln 5635(c)(4) entsprechen.
- Company demonstrates ability to attract new talent with competitive equity compensation
- Structured vesting schedule helps retain employees over the long term
- Potential dilution of existing shareholders due to additional 113,800 shares being issued
The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250314126000/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
What is the exercise price for Scholar Rock's (SRRK) new inducement stock options?
How many shares were granted in SRRK's latest employee inducement awards?
What is the vesting schedule for SRRK's new inducement stock options?
How do the restricted stock units (RSUs) vest in Scholar Rock's new inducement grants?
